Document is current
Any future updates will be listed below
-
Authors
Ai, Xinghao
Song, Zhengbo
Wu, Lin https://orcid.org/0000-0001-7078-7767
Zhou, Aiping
Cheng, Di
Zong, Hong
Wu, Heshui
Niu, Zuoxing
Sun, Yuping
Zhu, Lingjun
Li, Zhiwei
Deng, Yanhong
Yuan, Ying https://orcid.org/0000-0002-3922-9553
Qu, Xiujuan
Zhao, Haitao https://orcid.org/0000-0002-3444-8044
Du, Yingying
Li, Ziming
Wang, Yu
Shen, Haige
Zhu, Huaqiang
Zheng, Chanli
Wang, Shuang
Cui, Zhao
Tai, Lingyu
- License Information
-
More Information
Article History
Received: 7 January 2026
Accepted: 1 July 2026
First Online: 15 September 2026
Ethics
Competing interests: S.L. reports research funding from AstraZeneca, Hutchison, Bristol Myers Squibb (BMS), Heng Rui, BeOne Medicines, Roche and Hansoh Pharma; consulting fees from AstraZeneca, Pfizer, Boehringer Ingelheim, Hutchison MediPharma, Simcere, Zai Lab, GenomiCare Consulting, Yuhan Corporation, PRIME Oncology, Menarini Group and Roche; and honorarias as an invited speaker from AstraZeneca, Roche, Hansoh Pharma and Hengrui Therapeutics. Y. Du reports research funding from Innovent Biologics and Anke Biotechnology. Y.W., H.S., H. Zhu, C.Z., S.W., Z.C. and L.T. report employment and stock or stock options with GenFleet Therapeutics. The other authors declare no competing interests.
